
|Slideshows|September 4, 2018
Antipsychotics-To Respond or Not to Respond?
Author(s)Brian Miller, MD, PhD, MPH
A new study brings us closer to answering why antipsychotics are successful in treating schizophrenia in some patients and not in others.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease
2
Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia
3
Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety
4
DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial
5









